Adhesion of human platelets to serum amyloid A

Simcha Urieli-Shoval, George Shubinsky, Reinhold P. Linke, Mati Fridkin, Israel Tabi, and Yaacov Matzner

Serum amyloid A (SAA) is an acute phase reactant, and its level in the blood is elevated to 1000-fold as part of the response of the body to various injuries, including trauma, infection, inflammation, and neoplasia. The SAA proteins are expressed primarily in the liver, but extrahepatic expression was described, including in cells of human atherosclerotic lesions, as well as in the epithelium. SAA contains binding sites for the extracellular matrix (ECM) components laminin and heparin/heparan sulfate as well as YIGSR-like and RGD-like adhesion motifs (YIGSDKYF-HARGNY, residues 29 to 42). The latter is present at the turn of an α-helix, in a region that is highly conserved through evolution. SAA was reported to inhibit platelet aggregation, to induce adhesion of mononuclear and polymorphonuclear leukocytes, to induce matrix metalloproteinases, and to serve as their substrate. SAA-derived peptides were reported to inhibit T-lymphocyte attachment to ECM proteins. Nevertheless, the physiologic role of SAA as an ECM-associated and/or adhesion protein is not well established.

The major integrin receptor expressed on platelet membrane, αIIbβ3 (platelet receptor GPIIb/IIIa), plays a critical role in hemostasis and thrombosis by mediating platelet-platelet and platelet-matrix protein interactions. The RGD (arginine-glycine-aspartic acid) adhesion motif is present in fibronectin and other matrix adhesive proteins, including fibrinogen, vitronectin, and von Willebrand factor, and mediates the adhesive interactions of platelets and cells (ie, leukocytes and endothelial cells) by cell surface integrin receptors, including αIIbβ3. In this study we demonstrate the adhesion of human platelets to SAA and show that human washed platelets adhere to immobilized SAA in an RGD- and αIIbβ3-dependent manner. Furthermore, SAA-derived peptide inhibited platelet adhesion to subendothelial ECM protein, fibronectin.

Materials and methods

Antibodies and peptides

Antibodies used in the adhesion assays were as follows: anti-αIIbβ3 (c7E3Fab/abciximab/ReoPro [Eli-Lilly, Centocor, Leiden, The Netherlands]) and 10E5 (a gift from Dr B. S. Coller, Mount Sinai School of Medicine, New York, NY), anti-αVβ3 LM609 (Chemicon International, Temecula, CA), anti-SAA antibodies (clones mc29 and mcl) prepared and characterized as previously described, and control normal mouse immunoglobulin G (IgG; Zymed Laboratories, San Francisco, CA). Antibodies used in flow cytometry were as follows: anti-αIIb/CD41 (clone 5B12) and control mouse IgG were from DAKO Corporation (Carpinteria, CA) and fluorescein isothiocyanate (FITC)–conjugated goat anti-mouse IgG.

From the Hematology Unit, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel; the Flow Cytometry Unit, Hematology Laboratory and Institute of Hematology, Soroka University Medical Center, Beer-Sheva, Israel; the Max-Planck-Institut für Biochemie, Martinsried, Germany; and the Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel.

Submitted March 20, 2001; accepted October 12, 2001.

Yaacov Matzner died on November 24, 2001.

Supported by the Israel Cancer Research Fund, the Israel Science Foundation (grant 686/00-1), the Israel Cancer Association, the Israel Ministry of Absorption, and the Deutsche Forschungsgemeinschaft, Bonn, Germany (grant Li 247/12-3).

Reprints: Simcha Urieli-Shoval, Hematology Unit, Hadassah University Hospital, Mount Scopus, Jerusalem 91240, Israel; e-mail: matzner@cc.huji.ac.il.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

© 2002 by The American Society of Hematology
was from Jackson ImmunoResearch Laboratories (West Grove, PA). The secondary antibody used in Western blot analysis was a horseradish peroxidase–conjugated goat anti–mouse IgG (Jackson ImmunoResearch Laboratories). RGD containing peptides GRGDSP and GRGESP were purchased from GibcoBRL (Gaithersburg, MD). SAA-derived peptides used were as follows (in single-letter code): amino acids 29 to 42 (YIGSKDFYHARGNY), amino acids 28 to 40 (NYIGSKDFYHARG), and amino acids 83 to 104 (NEWRGSKDPNHFKRGPLPEKY), all synthesized, purified by high-performance liquid chromatography, and characterized by amino acid composition analysis as previously described. Additional control peptides included scrambled RGD (DGPSSGR), reverse RGD (PSDGRG), scrambled SAA peptide 29 to 42 (NYAGRKFIHYSGDYI), reverse 29 to 42 (YNGRAHYFKDSGY), and peptide-enclosing RGK (AARGNA). Other materials Human recombinant SAA (PeproTech, Rocky Hill, NJ), previously used in in vitro studies, was dissolved in d-H2O.16,22 Human plasma fibronectin was from GibcoBRL; and human fibrinogen (type I), human thrombin, and human recombinant C5a were purchased from Sigma (St Louis, MO). The 96-well titer plates (Maxi Sorp) were from Nunc (Naperville, IL). Transfected human melanoma cells, MO-oBb (expressing αIbb3 integrin receptor) and M21L4 (expressing αVb3 integrin receptor) were a gift from Dr Mark H. Ginsberg (The Scripps Research Institute, La Jolla, CA). They were maintained in Dulbecco modified Eagle medium (Biological Industries, Kibbutz Beit Haemek, Israel), supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heat-inactivated fetal calf serum (GibcoBRL). Other chemicals were of reagent grade from Sigma.

Preparation of platelets Platelets were purified from fresh blood obtained from healthy human donors (men and women, aged 27 to 51 years) who had not taken any medication for at least 2 weeks. Blood was drawn in 3.8% buffered citrate solution (7:1 vol/vol). Washed platelets were prepared as described and resuspended in Tyrode buffer (NaCl 140 mM, KCl 2.7 mM, NaHCO3 11.9 mM, NaH2PO4 0.36 mM, CaCl2 2 mM, MgCl2 1 mM, glucose 5.4 mM, bovine serum albumin [BSA] 1 mg/mL, pH 7.3). Platelets were studied microscopically to ensure the absence of platelet aggregates and minimal presence of contaminating cells. They were counted (COULTER STKS, Coulter Electronics, Hialeah, FL) and adjusted to 3 to 4 × 10^7 platelets/mL in Tyrode buffer. The white blood cell count was 1 to 2 cells per 1000 platelets.

Adhesion of platelets Platelet adhesion was carried out as described.25 Wells of 96-well titer plates were precoated (overnight at 4°C) with 50 μL of 50 μg/mL solution of each of the adhesive proteins, BSA, SAA, fibronectin, or fibrinogen and blocked (1 hour at 37°C) with Tyrode buffer containing 1% BSA. Platelet suspension (100 μL containing 3 to 4 × 10^7 platelets) was added to the precoated wells, platelets were allowed to adhere (1 hour at 37°C), and wells were then washed with Tyrode buffer to remove unattached platelets. Adherent platelets were fixed and stained in 2% toluidine blue/4% paraformaldehyde (30 minutes at 37°C), and, after rinsing in tap water until the washing was clear, solubilized with 100μL 1% sodium dodecyl sulfate (SDS). Absorbance at 595 nm was read in a spectrophotometer (UVICON 930; Kontron Instruments, Zurich, Switzerland). This method of staining was adapted after initial experiments showed its comparability to other methods (staining platelet-derived protein26 and measuring platelet acid phosphatase activity). The acid phosphatase assay was used in some experiments (Figure 1) to quantitate the number of adherent platelets. Briefly, after the adhesion and washing procedure, as described above, the substrate solution (0.1 M citrate buffer pH 5.4, containing 5 mM p-nitrophenyl phosphate and 0.1% Triton X-100; 150 μL per well) was added and incubated for 1 hour at room temperature. The reaction was stopped, and the color was developed by the addition of 100 μL 2N NaOH, and absorbance at 405 nm was measured with a microplate reader (DYNATECH MR 3000; Dynatech Laboratories).

Adhesion of melanoma cells Adhesion of the transfected human melanoma cells was carried out as described earlier with modifications. Cells were detached by minimal trypsinization (Trypsin 0.25%/EDTA 0.05%; 1 to 2 minutes), washed, and resuspended in serum-free Dulbecco modified Eagle medium supplemented with 1 mg/mL BSA. Cell suspension (100 μL containing 1 × 10^6 cells) was added to wells of 96-well titer plates precoated with each of the adhesive proteins, BSA, SAA, and fibronectin and was allowed to adhere for 1 hour at 37°C. Nonadherent cells were rinsed off with phosphate-buffered saline (PBS) containing CaCl2 2 mM, MgCl2 1 mM (warmed to 37°C), and adherent cells were fixed and stained in 2% toluidine blue/4% paraformaldehyde (30 minutes at 37°C). Wells were then rinsed in tap water. Stained cells were solubilized in 100μL 1% SDS, and absorbance of the solution was measured at 595 nm in microplate reader. Experiments were performed in triplicates and repeated at least 3 times. When indicated, cells were preincubated (15 minutes at 37°C) with or without Mn2+/thrombin.

Western blot analysis Recombinant human SAA and C5a (control proteins) were loaded onto 15% SDS-polyacrylamide gel and run at reduced conditions. After electrophoretic separation, the proteins were transferred to nitrocellulose membrane. The membrane was probed with anti-SAA monoclonal antibody (clone mc29), treated with horseradish peroxidase–conjugated goat anti–mouse IgG, and developed with Chemiluminescence Luminol Reagent (Santa Cruz Biotechnology, Santa Cruz, CA).

Flow cytometry analysis Transfected human melanoma cells were stained for flow cytometry by using standard indirect procedure. Briefly, cells were detached by minimal trypsinization, washed, and adjusted to 1.5 × 10^6 cells/50 μL PBS containing CaCl2 2 mM, MgCl2 1 mM, and MnCl2 2 mM. Fifty-microliter cell suspensions were incubated (60 minutes at 4°C) with anti-αIIb/CD41 (clone 5B12), anti-αVβ3 (clone LM609), or control isotype-matched mouse IgG. Cells were then washed and stained with FITC-conjugated goat anti–mouse IgG. The samples were then washed, fixed in 1% formaldehyde, and analyzed in EPICS XL-MCL flow cytometer with System II (Beckman).
Coulter, Miami, FL) and EXPO32 software programs (Applied Cytometry Systems, Sheffield, United Kingdom). In experiments detecting the binding of soluble SAA, 50-μL cell suspensions were incubated (60 minutes at 37°C) with SAA or control BSA (each at 200 μg/mL). Suspensions were then washed and incubated with a mixture of anti-SAA antibodies (clones mc29 and mc1) or control mouse IgG, and the assay proceeded as above.

Statistical analysis

Unless otherwise indicated, data are presented as mean ± SEM from at least 3 independent experiments. Statistical significance was calculated by using the paired t test.

Results

Human washed platelets adhere to immobilized SAA

Human washed platelets were prepared by standard procedure24 and tested for their adhesion to immobilized proteins by using the microtiter plate adhesion assay.25,27 BSA served as a negative control for background adhesion, whereas fibronectin and fibrinogen served as positive controls. The number of platelets that adhered to the coated wells was quantified by using the acid phosphatase assay27 in which 1 optical density (absorbance at 405 nm) represents approximately 2 × 10⁶ platelets (Figure 1A). Significant adhesion of platelets to SAA was observed; the level of adhesion to SAA was comparable to fibronectin and lower than to fibrinogen (Figure 1B). The number of adherent platelets to all 3 adhesive substrates was proportional to the number of platelets added to the coated wells and was similar to the number reported by others.28 Adhesion to SAA was further enhanced by Mn²⁺ ions (1 mM) or the physiologic agonist thrombin (1 U/mL) (Figure 1C). Mn²⁺ at lower concentration was less effective in enhancing platelet adhesion to SAA (3.8-, 1.7-, and 0.8-fold enhancement for 1, 0.5, and 0.1 mM Mn²⁺, respectively [representative experiment]). Adhesion was not enhanced by treatment with 10 μM adenosine diphosphate (102% ± 8.2% compared with nontreated platelets [defined as 100%]). Platelets prepared by the Mustard method and resuspended in Tyrode buffer without apyrase become insensitive to adenosine diphosphate, as previously reported.24

Figure 2. Effect of anti-SAA antibody on platelet adhesion to SAA.

Figure 3. Effect of RGD peptides on platelet adhesion to SAA. Platelets were preincubated (15 minutes at 37°C) with peptides GRGDSP (III) or GRGESP (II) at the indicated concentrations and then added to BSA-, SAA- or fibronectin-coated wells. The results are expressed as a mean ± 1 SEM for 3 experiments, each designed with triplicates for each peptide concentration. In each experiment, 100% adhesion (control) is the adhesion achieved in the absence of the tested peptide after subtracting adhesion to BSA.

*P < .05, **P < .01 when comparing adhesion with and without the tested peptide.

Specificity of platelet adhesion to SAA

The specificity of platelet adhesion to SAA was studied using various approaches. In the first approach, SAA-coated wells preincubated with monoclonal anti-SAA antibody, mc29 (500 μg/mL for 1 hour) failed to support platelet adhesion. However, platelet adhesion to fibronectin-coated wells, similarly pretreated with mc29, was not inhibited (Figure 2A). The specificity of mc29 antibody19,20 was confirmed by Western blot analysis, demonstrating its recognition of SAA (more than 90% of the recombinant SAA consisted of a SAA monomer of expected size 12.5 kDa) but not of C5a, an unrelated protein of similar size (Figure 2B).

In the second approach, the peptide GRGDSP inhibited platelet adhesion to SAA in a dose-dependent manner, whereas the peptide GRGESP had no significant effect (Figure 3, upper panel). Furthermore, these peptides had similar differential effect on platelet adhesion to the control adhesion protein, fibronectin (Figure 3, lower panel). Additional control peptides, scrambled RGD (DGPSGR) and reverse RGD (PSDGRG), had no significant inhibitory effect on platelet adhesion to SAA (89% ± 7.2% and 96% ± 7.6% of control adhesion, respectively) or to fibronectin (90.6% ± 9.6% and 115% ± 7.3% of control adhesion, respectively).

In the third approach, antibody recognizing the platelet receptor αIIbβ3 (c7E3Fab)29 inhibited platelet adhesion to SAA in a dose-dependent manner, whereas control IgG had no significant effect (Figure 4, upper panel). Furthermore, these peptides had similar differential effect on platelet adhesion to the control adhesion protein, fibronectin (Figure 3, lower panel). Additional control peptides, scrambled RGD (DGPSGR) and reverse RGD (PSDGRG), had no significant inhibitory effect on platelet adhesion to SAA (89% ± 7.2% and 96% ± 7.6% of control adhesion, respectively) or to fibronectin (90.6% ± 9.6% and 115% ± 7.3% of control adhesion, respectively).

In a separate set of experiments the inhibitory effect of this antibody on adhesion of Mn²⁺-treated platelets to SAA was compared with its effect on adhesion of untreated platelets and was found to be significantly greater (53.1% ± 9.2% versus 33.2% ± 15.1%, respectively, P < .02). Because antibody c7E3Fab interacts with both αIIbβ3 and αVβ3 on platelets,20 a monoclonal antibody specific for αVβ3 (clone LM609) was tested and had no inhibitory effect on adhesion of platelets, whether untreated or Mn²⁺ treated, to SAA.
Furthermore, 10E5, a monoclonal antibody specific for αIIbβ₃, completely inhibited platelet adhesion to fibrinogen but was found less effective than antibody c7E3Fab in inhibiting adhesion to SAA. It partially inhibited adhesion of Mn²⁺-treated platelets (inhibition of 35% ± 8.5%, P < .05) and had no inhibitory effect on adhesion of nontreated platelets to SAA (not shown). The antibody 10E5 was found less potent than c7E3Fab in inhibiting other platelet functions.³¹

In the fourth approach, SAA-derived peptide 29 to 42 (YIGSDKYFHARGNY) inhibited platelet adhesion to SAA in a dose-dependent manner, whereas SAA peptides 28 to 40 (NYIGSDKYFHARG) and 83 to 104 (NEWGRSGKDPNHFRPAGLPEKY) had no significant effect (Figure 5, upper panel). Furthermore, SAA-derived peptide 29 to 42 also inhibited platelet adhesion to wells coated with the control adhesion protein, fibronectin (Figure 5, lower panel). Additional control peptides, scrambled 29 to 42 (NYAGRKFHYSGYY), reverse 29 to 42 (YNGRAHFYKDSGYI), and peptide enclosing RGN (AARGNAA), had no significant inhibitory effect on platelet adhesion to SAA (88% ± 5%, 93.4% ± 6%, and 93.8% ± 7.3% of control adhesion, respectively) or to fibronectin (82.7% ± 9.2%, 96.7% ± 3.2%, and 93% ± 3.8% of control adhesion, respectively).

**Discussion**

SAA is an acute phase plasma protein, and its level in the blood is elevated to 1000-fold in response of the body to various insults, including tissue injury and inflammation. SAA is an ECM-bound protein¹²,¹³ that induces migration and adhesion of human leukocytes,¹⁰⁻¹² and its derived peptides inhibit adhesion of leukocytes to ECM proteins.¹⁶ Because SAA expression was found in atherosclerotic...
lesions, including endothelial cells at the luminal sites of the vessels, it was postulated that SAA may modulate platelet aggregation or adhesion at the endothelial cell surface, thereby controlling platelet activity at vascular injury sites. Indeed, SAA was reported to inhibit thrombin-induced platelet aggregation; however, its role in platelet adhesion was not studied. Here we describe that immobilized SAA supports the adhesion of human platelets and its derived peptide inhibits platelet adhesion to the subendothelial ECM protein, fibronectin. These findings identify a novel adhesive ligand for platelets and implicate its role in platelet adhesion thereby in hemostasis and thrombosis.

The specificity of platelet adhesion to SAA is supported by the following findings. First, the level of adhesion to SAA was comparable to other platelet adhesive proteins, ie, fibronectin and fibrinogen. Furthermore, the physiologic agonist thrombin, as well as the artificial stimulus that mimics physiologic agonists, could enhance platelet adhesion to SAA.

Although the aspartic acid is very important for interactions with the peptides 28 to 40, containing incomplete RGD, and 83 to 104, the C-terminus of the protein lacking adhesion motif, had no effect. Although the aspartic acid is a functionally important amino acid, isosteric and capable of establishing efficient interactions, it is hydrogen bonding.

Figure 7. Flow cytometry of human melanoma cells expressing platelet adhesion receptors. (A) Flow cytometry of cells expressing integrin αⅡbβ3 (left panel) or αVβ3 (right panel) after incubation with either one of the antibodies, anti-αⅡb (clone 5B12), anti-αVβ3 (clone LM609), or control IgG. (B) Flow cytometry of αⅡbβ3-expressing cells after incubation with SAA or control BSA followed by staining with a mixture of anti-SAA antibodies (clones mc29 and mc1) or control IgG. (C) Flow cytometry of αⅡbβ3- and αVβ3-expressing cells, after incubation with SAA followed by staining with anti-SAA antibodies. Controls for αVβ3 cells were done as described in Figure B (not shown). One representative experiment of 3 performed is shown.

The role of αⅡbβ3 integrin in the adhesion of human platelets to SAA was further supported by examining the adhesion of 2 human melanoma cell lines transfected to express either αⅡbβ3 or αVβ3 integrin on their surface. Although fibronectin supported the adhesion of both cell lines, SAA supported the adhesion of αⅡbβ3-expressing cells only. Adhesion was Mn²⁺ dependent and could be inhibited by anti-αⅡbβ3 antibody. The αⅡbβ3-expressing cells interact not only with immobilized SAA but also with soluble SAA and bind SAA at higher levels compared with αVβ3-expressing cells as revealed by flow cytometry. Although soluble SAA also binds to cells lacking αⅡbβ3, ie, αVβ3 cells, this binding is not sufficient to induce adhesion to immobilized SAA. These results give further support to the suggestion that αⅡbβ3, but not αVβ3, is a receptor associated with adhesion of platelets and nucleated cells to SAA.

In conclusion, our data indicate that human platelets specifically adhere to SAA in an RGD- and αⅡbβ3-dependent manner. Furthermore, SAA-derived peptide inhibits platelet adhesion to SAA and to the subendothelial ECM protein fibronectin. Thus, SAA may have a role in modulating platelet adhesion at vascular injury sites by sharing platelet receptors with other platelet-adhesive proteins. Further investigation is required to elucidate the physiologic relevance of our findings in hemostasis and thrombosis.

Dr Yaacov Matzner tragically passed away in a plane crash on Saturday, November 24, 2001, returning home from a scientific meeting in Germany; his many contributions to hematology will be remembered, and his presence in our community will be greatly missed.—Ed

Acknowledgments

We thank Dr Mark H. Ginsberg, The Scripps Research Institute, for the transfected human melanoma cells and Dr Barry S. Coller, Mount Sinai School of Medicine, for the 10E5 antibodies.
References


Adhesion of human platelets to serum amyloid A

Simcha Urieli-Shoval, George Shubinsky, Reinhold P. Linke, Mati Fridkin, Israel Tabi and Yaacov Matzner